These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 30970612)

  • 1. Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease.
    Del Bello F; Giannella M; Giorgioni G; Piergentili A; Quaglia W
    Biomolecules; 2019 Apr; 9(4):. PubMed ID: 30970612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa-induced dyskinesia in Parkinson's disease: still no proof? A meta-analysis.
    Giannakis A; Chondrogiorgi M; Tsironis C; Tatsioni A; Konitsiotis S
    J Neural Transm (Vienna); 2018 Sep; 125(9):1341-1349. PubMed ID: 29352351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging drugs for levodopa-induced dyskinesia.
    Al Dakheel A; Beaulieu-Boire I; Fox SH
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):415-29. PubMed ID: 25146568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa in the treatment of Parkinson's disease: an old drug still going strong.
    Poewe W; Antonini A; Zijlmans JC; Burkhard PR; Vingerhoets F
    Clin Interv Aging; 2010 Sep; 5():229-38. PubMed ID: 20852670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
    Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
    Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current treatment and future prospects of dopa-induced dyskinesias.
    Mazzucchi S; Frosini D; Bonuccelli U; Ceravolo R
    Drugs Today (Barc); 2015 May; 51(5):315-29. PubMed ID: 26097904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
    Ko WKD; Li Q; Cheng LY; Morelli M; Carta M; Bezard E
    Eur J Pharmacol; 2017 Oct; 813():10-16. PubMed ID: 28739086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.
    Schaeffer E; Pilotto A; Berg D
    CNS Drugs; 2014 Dec; 28(12):1155-84. PubMed ID: 25342080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.
    Haaxma CA; Horstink MW; Zijlmans JC; Lemmens WA; Bloem BR; Borm GF
    J Parkinsons Dis; 2015; 5(4):847-53. PubMed ID: 26444087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
    Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noradrenergic drugs for levodopa-induced dyskinesia.
    Colosimo C; Craus A
    Clin Neuropharmacol; 2003; 26(6):299-305. PubMed ID: 14646609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-DOPA for Parkinson's disease-a bittersweet pill.
    Lane EL
    Eur J Neurosci; 2019 Feb; 49(3):384-398. PubMed ID: 30118169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.
    Bastide MF; Meissner WG; Picconi B; Fasano S; Fernagut PO; Feyder M; Francardo V; Alcacer C; Ding Y; Brambilla R; Fisone G; Jon Stoessl A; Bourdenx M; Engeln M; Navailles S; De Deurwaerdère P; Ko WK; Simola N; Morelli M; Groc L; Rodriguez MC; Gurevich EV; Quik M; Morari M; Mellone M; Gardoni F; Tronci E; Guehl D; Tison F; Crossman AR; Kang UJ; Steece-Collier K; Fox S; Carta M; Angela Cenci M; Bézard E
    Prog Neurobiol; 2015 Sep; 132():96-168. PubMed ID: 26209473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist.
    Zhang J; Tan LC
    Curr Neuropharmacol; 2016; 14(4):356-63. PubMed ID: 26644151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
    Fox S; Silverdale M; Kellett M; Davies R; Steiger M; Fletcher N; Crossman A; Brotchie J
    Mov Disord; 2004 May; 19(5):554-60. PubMed ID: 15133820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
    Müller T
    Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
    Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.